While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...

Samsung Biologics (KRX: 207940.KS), a global contract manufacturing and development organization (CDMO), today announced that ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

"The addition of this five-partner team extends the capabilities of our 200-plus lawyer IP team," Morgan Lewis’ global IP ...

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

The number of clinical trials in which AI designed or repurposed molecules, or targeted diseases, has more than doubled since ...

Middle molecules with a molecular weight of more than 1,000 are difficult to synthesize due to multiple steps and time-consuming nature, demanding the development of a new approach that can overcome ...

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

Deborah McElhone, Head of Sustainability (Pharma) from CPI, argues that process intensification is a game changer for the ...